AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine

Thursday, June 08, 2017 | Headache & Pain , Phase 3/4 Trials , Research and Publications


A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromorphone. The randomized, double-blind, comparative study was conducted in two emergency departments (EDs) in New York City. Qualifying patients visiting the ED for acute migraine treatment were assigned to receive prochlorperazine 10 mg plus diphenhydramine 25 mg, or hydromorphone 1 mg. Results showed that sustained headache relief was achieved by significantly more patients in the prochlorperazine group (60 percent) compared to the hydromorphone group (31 percent). The trial was halted early because the results were clear and continued administration of the less-effective treatment, hydromorphone, would raise ethical issues.

Next Story

Comments

You must be logged in to leave a comment.